Samsung’s president says semiconductor supply issues and rising prices will force the company to consider repricing its products. This comes as Samsung aims to double its AI-powered devices to 800 million this year.
According to CNBC, Nvidia has unveiled its next-generation Rubin (R100) AI architecture, locking in its roadmap through 2027. The analysis highlights Nvidia’s exceptional growth metrics and presents a bullish options trade targeting a move to $220-$250.
Spotify is doubling down on social features within its app. The new “Listening Activity” shows friends what you’re streaming in real time, while “Request to Jam” lets Premium users invite others to a collaborative listening session. Both features are rolling out now via the Messages system.
Samsung’s mobile chief is warning of “one of the harshest pricing situations in memory,” signaling likely price increases for smartphones. The company is caught between soaring component costs and a critical product launch against a dominant Apple.
A pro-Russian hacktivist group is coordinating sustained denial-of-service attacks using a volunteer botnet. Their tool, DDoSia, allows anyone to join in, turning geopolitical tension into disruptive cyber campaigns. It’s more about persistent harassment than outright destruction.
Logitech’s configuration software for Mac broke after the company let a critical security certificate expire. The company has released a manual patch, calling the oversight an “inexcusable mistake.”
Meta’s planned $2 billion acquisition of AI startup Manus is facing a review by Chinese regulators. The concern is whether the deal violates the country’s technology export controls, even though Manus has since moved to Singapore.
The private markets are heading for a year of stark contrasts. According to Fortune’s survey, capital is concentrating at the top, the middle is collapsing, and AI startups face a brutal reckoning. Meanwhile, private equity expects a 20% volume jump and a new focus on exits.
In a major move for precision oncology, Amgen is acquiring UK biotech Dark Blue Therapeutics. The deal, valued at up to €718 million, centers on a promising leukemia drug candidate currently in pre-clinical studies.
Investment firm Baird has upgraded chemical manufacturer Albemarle to ‘outperform’ from ‘neutral’. Analyst Ben Kallo nearly doubled his price target to $210, implying a potential 33% upside from current levels.
